Caption Management’s BioMarin Pharmaceuticals BMRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $2.86M | Buy |
+50,000
| New | +$2.74M | 0.01% | 781 |
|
|
2025
Q4 | – | Sell |
-52,000
| Closed | -$2.82M | – | 1594 |
|
|
2025
Q3 | $2.82M | Buy |
52,000
+26,500
| +104% | +$1.52M | 0.02% | 708 |
|
|
2025
Q2 | $1.4M | Sell |
25,500
-18,000
| -41% | -$1.06M | 0.02% | 833 |
|
|
2025
Q1 | $3.08M | Sell |
43,500
-1,500
| -3% | -$101K | 0.03% | 539 |
|
|
2024
Q4 | $2.96M | Buy |
+45,000
| New | +$3.01M | 0.03% | 557 |
|
|
2024
Q3 | – | Sell |
-47,700
| Closed | -$3.93M | – | 1288 |
|
|
2024
Q2 | $3.93M | Buy |
47,700
+32,700
| +218% | +$2.72M | 0.06% | 322 |
|
|
2024
Q1 | $1.31M | Buy |
+15,000
| New | +$1.34M | 0.02% | 668 |
|
|
2023
Q4 | – | Sell |
-25,300
| Closed | -$2.24M | – | 1356 |
|
|
2023
Q3 | $2.24M | Sell |
25,300
-219,200
| -90% | -$19.5M | 0.03% | 549 |
|
|
2023
Q2 | $21.2M | Buy |
244,500
+108,300
| +80% | +$10.2M | 0.38% | 55 |
|
|
2023
Q1 | $13.2M | Buy |
136,200
+94,200
| +224% | +$9.77M | 0.26% | 87 |
|
|
2022
Q4 | $4.35M | Sell |
42,000
-18,000
| -30% | -$1.69M | 0.07% | 334 |
|
|
2022
Q3 | $5.09M | Buy |
+60,000
| New | +$5.34M | 0.07% | 345 |
|
|
2022
Q2 | – | Sell |
-72,500
| Closed | -$5.59M | – | 1468 |
|
|
2022
Q1 | $5.59M | Buy |
72,500
+30,000
| +71% | +$2.51M | 0.07% | 380 |
|
|
2021
Q4 | $3.75M | Buy |
+42,500
| New | +$3.51M | 0.04% | 550 |
|
|
2021
Q2 | – | Sell |
-140,400
| Closed | -$10.6M | – | 1307 |
|
|
2021
Q1 | $10.6M | Sell |
140,400
-226,400
| -62% | -$18.5M | 0.23% | 105 |
|
|
2020
Q4 | $32.2M | Buy |
366,800
+148,700
| +68% | +$11.8M | 0.73% | 17 |
|
|
2020
Q3 | $16.6M | Buy |
218,100
+152,100
| +230% | +$15.4M | 0.39% | 47 |
|
|
2020
Q2 | $8.14M | Sell |
66,000
-138,000
| -68% | -$13.7M | 0.27% | 90 |
|
|
2020
Q1 | $17.2M | Buy |
204,000
+59,900
| +42% | +$5.16M | 0.97% | 7 |
|
|
2019
Q4 | $12.2M | Buy |
+144,100
| New | +$10.9M | 0.41% | 46 |
|
|
2019
Q3 | – | Sell |
-38,000
| Closed | -$3.25M | – | 714 |
|
|
2019
Q2 | $3.25M | Buy |
38,000
+24,500
| +181% | +$2.1M | 0.16% | 175 |
|
|
2019
Q1 | $1.2M | Sell |
13,500
-20,600
| -60% | -$1.91M | 0.07% | 314 |
|
|
2018
Q4 | $2.9M | Buy |
+34,100
| New | +$3.24M | 0.23% | 130 |
|
|
2018
Q3 | – | Sell |
-10,000
| Closed | -$942K | – | 515 |
|
|
2018
Q2 | $942K | Hold |
10,000
| – | – | 0.07% | 257 |
|
|
2018
Q1 | $811K | Buy |
+10,000
| New | +$858K | 0.12% | 165 |
|
Other funds holding BMRN
VPC
Caption Management's BMRN Position: Q2 2026 in Review
Caption Management reduced its BioMarin Pharmaceuticals (BMRN) stake by 61% in Q2 2026, selling an estimated $1.86M and leaving 21,400 shares worth $1.22M. The position accounts for 0.01% of the portfolio, ranked #1061.
Caption Management first reported a position in BMRN in Q4 2017 and has held it in 18 quarters since. The position peaked at $9.87M in Q2 2023. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.
- Caption Management held 21,400 shares of BioMarin Pharmaceuticals worth $1.22M as of Q2 2026.
- Caption Management sold 33,900 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $1.86M.
- BioMarin Pharmaceuticals made up 0.01% of Caption Management's portfolio in Q2 2026, its #1061 holding.
- Caption Management first reported a position in BioMarin Pharmaceuticals in Q4 2017 and has held it in 18 quarters since.
- Caption Management's BioMarin Pharmaceuticals position peaked at $9.87M in Q2 2023.
- 565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.
Based on Caption Management's 13F filing for Q2 2026, filed 14 Aug 2026.